MAGnesium Effect With ANtiosteoporotic Drugs
MAGnesium Effect With ANtiosteoporotic Drugs
NCT ID: NCT05328154 Phase: PHASE2 Status: COMPLETED Enrollment: 45 Completion: 2024-12-19
Conditions
Osteoporosis, Postmenopausal
Interventions
Follow-up of patients with postmenopausal osteoporosis, with or without fractures, requiring initiation of injectable bisphosphonate therapy as part of their usual care, Follow-up of patients with postmenopausal osteoporosis, fractured or not, requiring initiation of injectable bisphosphonate therapy as part of care with magnesium supplementation
Summary
Randomized pilot clinical trial to demonstrate superiority of bisphosphonate-magnesium combination over bisphosphonates alone in postmenopausal osteoporosis in slowing bone remodeling as assessed by C-terminal telopeptide of bone collagen type 1 (CTX) dosage.
Primary Outcome
C-terminal telopeptides of collagen type 1 (CTX) dosage